Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially fatal disease. Little is known about the economic burden associated with CTEPH patients in the US.
The objective of this study was to estimate excess direct costs associated with privately insured patients with CTEPH in the US.
From a privately insured claims database (>8 million beneficiaries, 2002–7), 289 CTEPH patients were identified using the criteria: two or more claims for pulmonary hypertension (PH), International Classification of Diseases, ninth edition, clinical modification (ICD-9-CM) code 416.0 or 416.8; one or more claim for pulmonary embolism (ICD-9-CM: 415.1, V12.51; ICD-9 procedure: 38.7; Current Procedural Terminology [CPT]-4 code: 36010, 37620, 75825, 75940; Healthcare Common Procedure Coding System [HCPCS] code: C1880) within 12 months prior or 1 month after the initial PH claim (index date); one or more claim for right heart catheterization (RHC) within 6 months prior to any PH claim or one or more claim for echocardiogram within 6 months prior to a specialist-diagnosed PH claim; aged 18–64 years. Patients with CTEPH were matched demographically to controls without PH. Patients were followed as long as continuously eligible; mean follow-up in CTEPH patients was 21.5 months. Chi-squared tests were used to compare baseline co-morbidities. Wilcoxon rank-sum tests were used to compare direct (medical and pharmaceutical) patient-month costs to insurers.
The average age for CTEPH patients was 52.2 years, and 57.1 % were women. Compared with controls, CTEPH patients had significantly higher baseline rates of co-morbidities (e.g. essential hypertension, congestive heart failure and chronic pulmonary disease) and a higher mean Charlson Co-morbidity Index score. Mean direct patient-month costs (year 2007 values) were $US4782 for CTEPH patients and $US511 for controls (p< 0.0001). Sensitivity analysis restricting the sample to patients diagnosed following RHC yielded a 15% increase in excess costs relative to the original sample. Regarding cost drivers, inpatient services accounted for 54%, outpatient and other services for 33% and prescription drugs for 11% of total direct healthcare costs per patient-month in CTEPH patients. Circulatory-/respiratory-related patient-month costs were $US2496 among CTEPH patients and $US128 among controls (p< 0.0001).
CTEPH patients had substantially higher costs and co-morbidity than matched controls, with circulatory-/respiratory-related costs accounting for 55% of excess costs. The high burden of illness suggests opportunities for savings from improved management.
- McLaughlin, V.V., Archer, S.L., Badesch, D.B. (2009) ACCF/AHA 2009 expert consensus document on pulmonary arterial hypertension. J Am Coll Cardiol 53: pp. 1573-619 CrossRef
- Simonneau, G., Robbins, I.M., Beghetti, M. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: pp. S43-54 CrossRef
- Hoeper, M.M., Mayer, E., Simonneau, G. (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113: pp. 2011-20 CrossRef
- Pengo, V., Lensing, A.W., Prins, M.H. (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350: pp. 2257-64 CrossRef
- Lang, I.M. (2004) Chronic thromboembolic pulmonary hypertension: not so rare after all. N Engl J Med 350: pp. 2236-8 CrossRef
- Suntharalingam, J., Treacy, C.M., Doughty, N.J. (2008) Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 134: pp. 229-36 CrossRef
- Jaïs, X., D’Armini, A.M., Jansa, P. (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 16: pp. 2127-34 CrossRef
- Seyfarth, H.J., Halank, M., Wilkens, H. (2010) Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol 99: pp. 553-6 CrossRef
- Ribeiro, A., Lindmarker, P., Johnsson, H. (1999) Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 99: pp. 1325-30 CrossRef
- Charlson, M.E., Pompei, P., Ales, K.L. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: pp. 373-83 CrossRef
- Romano, P.S., Roos, L.L., Jollis, J. (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 46: pp. 1075-9 CrossRef
- Consumer price index for medical care.
- Kirson, N.Y., Birnbaum, H.G., Ivanova, J.I. (2011) Excess costs associated with patients with pulmonary arterial hypertension in US privately insured population. Appl Health Econ Health Policy 9: pp. 293-303 CrossRef
- Birnbaum, H.G., Mattson, M.E., Kashima, S. (2011) Prevalence rates and costs of metabolic syndrome and associated risk factors using employees’ integrated laboratory data and health care claims. J Occup Environ Med 53: pp. 27-33 CrossRef
- Macchia, A., Marchioli, R., Marfisi, R. (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153: pp. 1037-47 CrossRef
- Ghofrani, H.A., Wilkins, M.W., Rich, S. (2008) Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 118: pp. 1195-201 CrossRef
- Galie, N., Palazzini, M., Manes, A. (2010) Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 31: pp. 2080-6 CrossRef
- White, R.H. (2003) The epidemiology of venous thromboembolism. Circulation 107: pp. I4-8
- Silverstein, M.D., Heit, J.A., Mohr, D.N. (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 158: pp. 585-93 CrossRef
- National Institutes of Health, US Department of Health and Human Services. What is pulmonary embolism [online]. Available from URL: http://www.nhlbi.nih.gov/health/dci/Diseases/pe/pe_what.html [Accessed 2009 Nov 5]
- Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
Applied Health Economics and Health Policy
Volume 9, Issue 6 , pp 377-387
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA, 02199, USA
- 2. Analysis Group, Inc., New York, NY, USA
- 3. Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA